Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

John Reyes

Geriatric Medicine Oyster Bay, NY Medical Doctor

NPI 1295888709 CMS profile 13882

15A Berry Hill Rd, Ste 303, Oyster Bay, NY 11771

Open in the dashboard

General payments

$364

12 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Reyes of Oyster Bay, NY is reported in the CMS Open Payments database as having received $364 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 62nd percentile of Geriatric Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $19 1
2023 General $290 8
2022 General $24 1
2021 General $15 1
2019 General $16 1

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Reyes
  • Geriatric Medicine median
  • Middle half of Geriatric Medicine
  • National median

In program year 2025, general payments to John Reyes were reported at $19. Among 512 Geriatric Medicine profiles paid that year, the median was $120 and the middle half received between $37 and $350.

Show as a table
Year John Reyes Geriatric Medicine median Middle half National median
2019 $16 $96 $28–$339 $163
2020 $0 $99 $28–$262 $114
2021 $15 $94 $27–$318 $132
2022 $24 $103 $34–$338 $149
2023 $290 $109 $39–$320 $160
2024 $0 $125 $36–$371 $164
2025 $19 $120 $37–$350 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $160 8 payments
  2. Apollo Endosurgery US Inc $149 1 payment
  3. Xeris Pharmaceuticals, Inc. $24 1 payment
  4. AstraZeneca Pharmaceuticals LP $16 1 payment
  5. Abbott Laboratories $15 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $364 12 payments
Products named General payments · program years 2019–2025
  1. OverStitch Endoscopic Suturing System $149 1 payment
  2. TRELEGY ELLIPTA $113 5 payments
  3. SHINGRIX $48 3 payments
  4. AREXVY Respiratory $29 2 payments
  5. GVOKE HYPOPEN $24 1 payment
  6. AREXVY Respiratory $19 1 payment
  7. FreeStyle Libre 2 $15 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 260 drugs

Part D claims

22,342

Median for Internal Medicine: 777

Drug cost

$1,873,425

Median for Internal Medicine: $73,373

Branded share of claims

18.8%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 508 $271,546
Mounjaro Tirzepatide Brand 213 $244,444
Jardiance Empagliflozin Brand 146 $157,250
Ozempic Semaglutide Brand 58 $104,878
Farxiga Dapagliflozin Propanediol Brand 165 $96,931
Oxycontin Oxycodone Hcl Brand 41 $67,581
Synjardy Empagliflozin/Metformin Hcl Brand 105 $66,332
Januvia Sitagliptin Phosphate Brand 83 $57,247
Rybelsus Semaglutide Brand 43 $55,954
Santyl Collagenase Clostridium Hist. Brand 71 $40,317

The 10 drugs with the highest cost, of 260 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 42 billing codes

Paid by Medicare

$440,722

Of which drugs: $11,587

Medicare patients

999

Average age 78

Services billed

5,451

537 women, 462 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Ischemic heart disease 43%
Diabetes 32%
Depression 30%
Atrial fibrillation 28%
Chronic kidney disease 27%
Heart failure 23%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Vaccine for influenza for injection into muscle 90662 Office 82 84 $6,814
Pcv20 vaccine im 90677 Office 16 16 $4,591

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Geriatric Medicine in New York

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record